

Active Pharmaceutical Ingredient (API) Market Size, Share & Trends Analysis By Type, By Manufacturer, By types of Synthesis, By type of Drug, By Therapeutic Application, Regional Outlook, Competitive Strategies and Segment Forecasts to 2030

https://marketpublishers.com/r/A656C9D7D37FEN.html

Date: February 2022 Pages: 207 Price: US\$ 4,250.00 (Single User License) ID: A656C9D7D37FEN

# Abstracts

The global active pharmaceutical ingredients market size is projected to reach USD 262.40 billion by 2030.

According to SPER Market Research, the global active pharmaceutical ingredients market estimated to reach USD 262.40 Bn by 2030 with a CAGR of 6.8%. Market growth is driven mainly by factors like rising drug R&D, the increasing incidence of chronic diseases, the growing importance of generics, and the increasing uptake of biopharmaceuticals. The growth of this market is going to be controlled by the unfavourable drug price control policies and high manufacturing costs.

COVID-19 Impact on the Active Pharmaceutical Ingredient (API) Market With the WHO declaring the COVID-19 outbreak a pandemic, a mix of established pharmaceutical and biopharmaceutical companies, as well as small start-ups, have stepped forward to develop treatments that target the infection. The economic and social burden of pandemics has prompted government bodies to increase funding for vaccine development on a global scale. Increase in funding and research for development of pharmaceutical products will drive growth for the market. However, corona virus outbreak has disrupted business and economic activities globally in the first quarter of 2020. It is expected to have a short-term impact on the active pharmaceutical ingredients market to a certain extent.



Scope of the report:

Market size available for years 2019-2030

Base year considered 2021

Forecast period 2022-2030

Segments covered

By type, By Manufacturer, By types of Synthesis, By types of Drug, By types of Therapeutic action, By Region

Geographies covered North America, Europe, Asia, and Rest of the World

#### **Companies Covered**

Pfizer, Inc. (US), Novartis International AG (Switzerland), Sanofi (France), Boehringer Ingelheim (Germany), Bristol-Myers Squibb (US), Teva Pharmaceutical Industries Ltd. (Israel), Eli Lilly and Company (US), GlaxoSmithKline plc (UK), Merck & Co., Inc. (US), AbbVie Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), AstraZeneca (UK), Cipla, Inc. (India), Mylan N.V. (US), Dr. Reddy's Laboratories Ltd. (India), Sun Pharmaceutical Industries Ltd. (India), API Pharma Tech (India), BDR Pharmaceuticals Internationals Pvt. Ltd. (India), Sreepathi Pharmaceuticals Limited (India), Shilpa Medicare Limited (India)

Driver: Increasing incidence of chronic diseases

The incidence of chronic diseases such as diabetes, coronary artery disease, chronic obstructive pulmonary disease (COPD), asthma, hepatitis, arthritis, and cancer has increased globally. This can be attributed to the rising geriatric population across the globe. Changing lifestyles, and dietary changes as a result of rapid urbanization. According to the International Diabetes Federation, in 2019, 463 million people worldwide were diagnosed with diabetes. Moreover, the number of new cancer cases per year is expected to rise to 23.6 million by 2030.

Challenges: High manufacturing costs



The high manufacturing cost of APIs (chemical synthesis of APIs also often requires expensive and uncommon building blocks and raw materials), the costs of obtaining regulatory approvals are relatively higher for firms with small volumes these are major challenges for growth of this market in low- and medium-income countries with poor reimbursement scenarios.

#### Opportunity: Emerging biosimilars market

The rising incidence of various diseases, the increasing number of off-patent biologic drugs, positive outcomes in ongoing clinical trials for biosimilars, and the rising demand for biosimilars in different therapeutic applications (such as rheumatoid arthritis and blood disorders) are the major factors driving the growth of the biosimilars market. The expiration of patents and other intellectual property rights for originator biologics over the next decade is expected to open up opportunities for biosimilars to enter the market.

Active Pharmaceutical Ingredient (API) Market, By Type: Based on the type, APIs market is segmented as; Innovative APIs, Generic APIs.

#### APIs Market, By Type of Manufacturer:

Based on the type of Manufacturer, APIs market is segmented as; Captive Manufacturers, Merchant Manufacturers (Merchant Manufacturers Market, by Type, Innovative Merchant API Manufacturers, Generic Merchant API Manufacturers, Merchant Manufacturers Market by Type of Synthesis, Synthetic APIs, Biotech APIs).

#### APIs market, by Type of Synthesis:

Based on the type of Synthesis, APIs market is segmented as; Synthetic APIs Market (Synthetic APIs Market, by Type, Innovative Synthetic APIs, Generic Synthetic APIs), Biotech APIs Market (Biotech APIs Market, by Type, Innovative Biotech APIs, Biosimilars, Biotech APIs Market, by Product, Monoclonal Antibodies, Hormones, Cytokines, Fusion, Proteins, Therapeutic Enzymes, Vaccines, Blood Factors, Biotech APIs Market, by, Expression System, Mammalian Expression Systems, Microbial Expression Systems, Yeast Expression Systems, Insect Expression Systems, Plant expression systems).

#### APIs Market, by Type of Drug:

Based on the type of Drugs, APIs market is segmented as; Prescription Drugs, Over-thecounter Drugs.

APIs Market, by Therapeutic Application: Based on the type of Therapeutic Application, APIs market is segmented as;



Communicable Diseases, Oncology, Diabetes, Cardiovascular Disease, Pain management, Respiratory Diseases, Other Therapeutic Applications (Orthopedics, Urology and Nephrology, Ophthalmology, Pulmonology, Women's Health, and Gastroenterology).

API Market, by Region:

North America owns the largest share of this market due to prevalence of the growing incidence of preventable chronic diseases, increasing government focus on generic drugs, rising demand for biologics and specialty drugs, and technological advancements in the manufacturing processes of APIs.



# Contents

- **1. INTRODUCTION**
- 2. RESEARCH METHODOLOGY
- **3. EXECUTIVE SUMMARY**

## 4. MARKET OVERVIEW

- 4.1. Introduction
- 4.2. Market Dynamics
  - 4.2.1. Drivers
  - 4.2.2. Restraints
  - 4.2.3. Opportunities
  - 4.2.4. Challenges
- 4.3. COVID-19 Impact on the Active Pharmaceutical Ingredient (API) Market
- 4.4. Market Trends

# 5. ACTIVE PHARMACEUTICAL INGREDIENT (API) MARKET, BY TYPE, 2019-2030 (USD MILLION)

- 5.1. Innovative APIs
- 5.2. Generic APIS

#### 6. APIS MARKET, BY TYPE OF MANUFACTURER, 2019-2030 (USD MILLION)

6.1. Captive Manufacturers

#### 7. MERCHANT MANUFACTURERS

- 7.1.1. Merchant Manufacturers Market, by Type
- 7.1.2. Innovative Merchant API Manufacturers
- 7.1.3. Generic Merchant API Manufacturers
- 7.1.4. Merchant Manufacturers Market, by Type of Synthesis
- 7.1.5. Synthetic APIs
- 7.1.6. Biotech APIs

# 8. APIS MARKET, BY TYPE OF SYNTHESIS, 2019-2030 (USD MILLION)

Active Pharmaceutical Ingredient (API) Market Size, Share & Trends Analysis By Type, By Manufacturer, By types...



- 8.1. Synthetic APIs Market
  - 8.1.1. Synthetic APIs Market, by Type
  - 8.1.2. Innovative Synthetic APIs
  - 8.1.3. Generic Synthetic APIs
- 8.2. Biotech APIs Market
  - 8.2.1. Biotech APIs Market, by Type
  - 8.2.2. Innovative Biotech APIs
  - 8.2.3. Biosimilars
  - 8.2.4. Biotech APIs Market, by Product
  - 8.2.5. Monoclonal Antibodies
  - 8.2.6. Hormones
  - 8.2.7. Cytokines
  - 8.2.8. Fusion Proteins
  - 8.2.9. Therapeutic Enzymes
  - 8.2.10. Vaccines
  - 8.2.11. Blood Factors
  - 8.2.12. Biotech APIs Market, by Expression System
  - 8.2.13. Mammalian Expression Systems
  - 8.2.14. Microbial Expression Systems
  - 8.2.15. Yeast Expression Systems
  - 8.2.16. Insect Expression Systems
  - 8.2.17. Other Expression Systems (Plant expression systems)

#### 9. APIS MARKET, BY TYPE OF DRUG, 2019-2030 (USD MILLION)

- 9.1. Prescription Drugs
- 9.2. Over-the-counter Drugs

#### 10. APIS MARKET, BY THERAPEUTIC APPLICATION, 2019-2030 (USD MILLION)

- 10.1. Communicable Diseases
- 10.2. Oncology
- 10.3. Diabetes
- 10.4. Cardiovascular Disease
- 10.5. Pain management
- 10.6. Respiratory Diseases
- 10.7. Other Therapeutic Applications (Orthopedics, Urology and Nephrology,

Ophthalmology, Pulmonology, Women's Health, and Gastroenterology)



#### 11. API MARKET, BY REGION, 2019-2030 (USD MILLION)

11.1. North America

- 11.1.1. US
- 11.1.2. Canada
- 11.2. Europe
- 11.2.1. Germany
- 11.2.2. France
- 11.2.3. UK
- 11.2.4. Italy
- 11.2.5. Spain
- 11.2.6. Hungary
- 11.2.7. Rest of Europe
- 11.3. Asia
  - 11.3.1. Japan
  - 11.3.2. China
  - 11.3.3. India
  - 11.3.4. South Korea
  - 11.3.5. Rest of Asia
- 11.4. Rest of the World
- 11.5. Israel
- 11.6. Other countries

#### **12. COMPETITIVE LANDSCAPE**

- 12.1. Introduction
- 12.2. Market Share Analysis, By Key Players
- 12.3. Competitive Scenario
  - 12.3.1. Product Launches
  - 12.3.2. Partnerships, Collaborations and Agreements
  - 12.3.3. Acquisitions
  - 12.3.4. Expansions
  - 12.3.5. Other Developments

#### **13. COMPANY PROFILES**

- 13.1. AbbVie Inc. (US)
- 13.2. API Pharma Tech (India)



- 13.3. AstraZeneca (UK)
- 13.4. BDR Pharmaceuticals Internationals Pvt. Ltd. (India)
- 13.5. Boehringer Ingelheim (Germany)
- 13.6. Bristol-Myers Squibb (US)
- 13.7. Cipla, Inc. (India)
- 13.8. Dr. Reddy's Laboratories Ltd. (India)
- 13.9. Eli Lilly and Company (US)
- 13.10. F. Hoffmann-La Roche Ltd. (Switzerland)
- 13.11. GlaxoSmithKline plc (UK)
- 13.12. Merck & Co., Inc. (US)
- 13.13. Mylan N.V. (US)
- 13.14. Novartis International AG (Switzerland)
- 13.15. Pfizer, Inc. (US)
- 13.16. Sanofi (France)
- 13.17. Shilpa Medicare Limited (India)
- 13.18. Sreepathi Pharmaceuticals Limited (India)
- 13.19. Sun Pharmaceutical Industries Ltd. (India)
- 13.20. Teva Pharmaceutical Industries Ltd. (Israel)

#### **14. APPENDIX**



## I would like to order

Product name: Active Pharmaceutical Ingredient (API) Market Size, Share & Trends Analysis By Type, By Manufacturer, By types of Synthesis, By type of Drug, By Therapeutic Application, Regional Outlook, Competitive Strategies and Segment Forecasts to 2030

Product link: https://marketpublishers.com/r/A656C9D7D37FEN.html

Price: US\$ 4,250.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service: info@marketpublishers.com

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/A656C9D7D37FEN.html</u>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

\*\*All fields are required

Custumer signature \_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <u>https://marketpublishers.com/docs/terms.html</u>

To place an order via fax simply print this form, fill in the information below



and fax the completed form to +44 20 7900 3970